Effects of semaglutide treatment on the psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial
In this medfyle
In a small randomised study presented at EADV 2025, semaglutide showed significant reduction of PASI and inflammatory markers in people with psoriasis, obesity, and T2D. These findings suggest the systemic effects of GLP-1RA could be useful to manage multiple comorbidities – targeting both skin and metabolic components.
About this Medfyle
©2025 Infomedica-Medfyle. All rights reserved.
Source: Effects of semaglutide treatment on the psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Petkovic-Dabic J. Presented at EADV 2025; P3550.
The information and data provided is for information purposes only. The author(s) of the original presentation had no involvement in the creation of this content.
